List of Forfivo Xl drug patents

Forfivo Xl is owned by Almatica.

Forfivo Xl contains Bupropion Hydrochloride.

Forfivo Xl has a total of 1 drug patent out of which 0 drug patents have expired.

Forfivo Xl was authorised for market use on 10 November, 2011.

Forfivo Xl is available in tablet, extended release;oral dosage forms.

The generics of Forfivo Xl are possible to be released after 25 June, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7674479 ALMATICA Sustained-release bupropion and bupropion/mecamylamine tablets
Jun, 2027

(4 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE ingredient

Market Authorisation Date: 10 November, 2011

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of FORFIVO XL before it's patent expiration?
More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in